Skip to contentpdufa.bio

BHV-1530 (FGFR3-directed ADC)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

BHV-1530 (FGFR3-directed ADC) is a Biohaven Ltd. program. Its next catalyst is a Readout on Nov 19, 2026.

BHVN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Biohaven Ltd. (BHVN). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Nov 19, 2026BHVN

Specialist biotech funds holding BHVN, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Avoro Capital Advisors2,750,000$36.7 millionfiled November 16, 2026
Cormorant Asset Management1,510,000$20.2 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is BHV-1530 (FGFR3-directed ADC)'s next FDA decision or readout?

The next tracked catalyst for BHV-1530 (FGFR3-directed ADC) is a Readout on Nov 19, 2026.

What happened at BHV-1530 (FGFR3-directed ADC)'s most recent FDA decision?

No FDA decision for BHV-1530 (FGFR3-directed ADC) is in our archive yet.

Who makes BHV-1530 (FGFR3-directed ADC)?

Biohaven Ltd. (BHVN).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.